Healthcare stocks fade as obesity-drug optimism fades
By Dow Jones Newswires
Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.
Viking Therapeutics shares (VKTX) gave back some of their recent gains amid skepticism about the biotech firm's attempt to compete with heavyweights such as Novo Nordisk on obesity drugs. Novo Nordisk (NVO) fell, shaving its gains for the year to date to around 25%.
Shares of Eiger BioPharmaceuticals (EIGR) plunged after the drug developer filed for chapter 11 bankruptcy with a deal in hand to sell its Zokinvy drug.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-01-24 2059ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?